Cargando…
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Adoptive cell therapy using T cell receptor-engineered T cells (TCR-T) is a promising approach for cancer therapy with an expectation of no significant side effects. In the human body, mature T cells are armed with an incredible diversity of T cell receptors (TCRs) that theoretically react to the va...
Autores principales: | Pang, Zhi, Lu, Man-man, Zhang, Yu, Gao, Yuan, Bai, Jin-jin, Gu, Jian-ying, Xie, Lu, Wu, Wei-zhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690996/ https://www.ncbi.nlm.nih.gov/pubmed/38037114 http://dx.doi.org/10.1186/s40364-023-00534-0 |
Ejemplares similares
-
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
por: Zhou, Weijun, et al.
Publicado: (2022) -
Neoantigen: A New Breakthrough in Tumor Immunotherapy
por: Zhang, Zheying, et al.
Publicado: (2021) -
TCR-T Immunotherapy: The Challenges and Solutions
por: Liu, Yating, et al.
Publicado: (2022) -
Engineering neoantigen vaccines to improve cancer personalized immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2022) -
The Value of Microbes in Cancer Neoantigen Immunotherapy
por: Tian, Junrui, et al.
Publicado: (2023)